Atrial fibrillation: modern approaches to staging and management of the disease
AbstractAtrial fibrillation is one of the most common arrhythmias among middle-aged and elderly people This disease can lead to multidirectional complications and reduce the quality of life.
As scientific knowledge accumulates, approaches to the management of patients with atrial fibrillation are undergoing changes: the focus of treatment of such patients is now gradually shifting towards rhythm control tactics for longest period possible. This becomes possible during interaction with the patient at the preclinical stage of atrial fibrillation, because aninhibition or delay of a further steady cascade of stages of atrial fibrillation is possible at this point. This stage, from the point of view of patient care, has not currently been studied; there is only general information about the primary prevention of the disease.
In addition, even if arrhythmia is already present, the clinician is faced with the rather difficult task of determining the optimal strategy, including the choice between medication and interventional tactics, due to a certain unpredictability of the treatment outcome, regardless of the patient’s premorbid background.
Keywords: atrial fibrillation; pre-disease; risk factors
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Obrezan A.G., Kholkina A.A. Atrial fibrillation: modern approaches to staging and management of the disease. [Cardiology: News, Opinions, Training]. 2024; 12 (3): 38–42. DOI: https://doi.org/10.33029/2309-1908-2024-12-3-38-42 (in Russian)
References
1. Arakelyan M.G., Bockeria L.A., Vasil’eva E. Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V., et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (7): 190–250. (in Russian)
2. Torgunakov A.P. Understanding the pre-disease is the key to preventing the disease. In: Sovremenniy mir, priroda i chelovek: sbornik materialov XX Mezhdunarodnoy nauchno-prakticheskoy konferentsii [Proceedings of the Scientific-Practical Conference «Modern Word; Nature and Man»]. Kemerovo, 2021: 374–91. (in Russian)
3. Algorithms of specialized medical care for patients with diabetes mellitus. I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 11th issue. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2S): 1–157. DOI: https://doi.org/10.14341/DM13042 (in Russian)
4. Uspensky Yu.P., Petrenko Yu.V., Gulunov Z.H., Shaporova N.L., Fominykh Yu.A., Niyazov R.M. Metabolic syndrome. Saint Petersburg: SPbGPMU, 2020: 76 p. (in Russian)
5. Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M., Deswal A., et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology. American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79 (17): e263–421. DOI: https://doi.org/10.1161/cir.0000000000001097
6. Joglar J.A., Chung M.K., Armbruster A.L., Benjamin E.J., Chyou J.Y., Cronin E.M., et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology. American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024; 149 (1): e1–156. DOI: https://doi.org/10.1161/cir.0000000000001218
7. Mohanty S., Mohanty P., Tamaki M., et al. Differential association of exercise intensity with risk of atrial fibrillation in men and women: evidence from a meta-analysis. J Cardiovasc Electrophysiol. 2016; 27: 1021–9. DOI: https://doi.org/10.1111/jce.13023
8. Allan V., Honarbakhsh S., Casas J.P., et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017; 117: 837–50. DOI: https://doi.org/10.1160/th16-11-0825
9. Aune D., Feng T., Schlesinger S., et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018; 32: 501–11. DOI: https://doi.org/10.1016/j.jdiacomp.2018.02.004
10. Aune D., Schlesinger S., Norat T., et al. Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. 2018; 25: 1437–51. DOI: https://doi.org/10.1177/2047487318780435
11. Aune D., Sen A., Schlesinger S., et al. Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017; 32: 181–92. DOI: https://doi.org/10.1007/s10654-017-0232-4
12. Jiang H., Mei X., Jiang Y., Yao J., Shen J., Chen T., et al. Alcohol consumption and atrial fibrillation risk: an updated dose-response meta-analysis of over 10 million participants. Front Cardiovasc Med. 2022; 9: 979982. DOI: https://doi.org/10.3389/fcvm.2022.979982
13. Liu X., Guo N., Zhu W., et al. Resting heart rate and the risk of atrial fibrillation. Int Heart J. 2019; 60: 805–11. DOI: https://doi.org/10.1536/ihj.18-470
14. Lunde E.D., Nielsen P.B., Riahi S., et al. Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. Expert Rev Cardiovasc Ther. 2018; 16: 857–73. DOI: https://doi.org/10.1080/14779072.2018.1533118
15. Tatarsky B.A., Napalkov D.A. Atrial fibrillation: a marker or risk factor for stroke. Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2023; 19 (1): 83–8. DOI: https://doi.org/10.20996/1819-6446-2023-01-06 (in Russian)
16. Goudis C., Daios S., Dimitriadis F., Liu T. CHARGE-AF: a useful score for atrial fibrillation prediction? Curr Cardiol Rev. 2023; 19 (2): e010922208402. DOI: https://doi.org/10.2174/1573403x18666220901102557
17. Kirchhof P., Camm A.J., Goette A., Brandes A., Eckardt L., Elvan A., et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383 (14): 1305–16. DOI: https://doi.org/10.1056/nejmoa2019422
18. Kirilova V.S., Stukalova O.V., Aparina O.P., Maykov E.B. The relationship between structural changes in the myocardium of the left atrium and the effectiveness of cryoablation in persistent atrial fibrillation. Aterotromboz [Atherothrombosis]. 2023; 13 (1): 93–104. (in Russian)
19. Marrouche N.F., Brachmann J., Andresen D., Siebels J., Boersma L., Jordaens L., et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378 (5): 417–27. DOI: https://doi.org/10.1056/nejmoa1707855
20. Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Poole J.E., et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321 (13): 1261–74. DOI: https://doi.org/10.3410/f.735328400.793558685
21. Mujović N., Dobrev D., Marinković M., et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020; 151: 104521. DOI: https://doi.org/10.1016/j.phrs.2019.104521
22. Maqdasy S., Benichou T., Dallel S., Roche B., Desbiez F., Montanier N., et al. Issues in amiodarone-induced thyrotoxicosis: update and review of the literature. Ann Endocrinol (Paris). 2019; 80 (1): 54–60. DOI: https://doi.org/10.1016/j.ando.2018.05.001
23. Tarzimanova A.I., Doshchitsin V.L. Antiarrhythmic therapy for atrial fibrillation: current guidelines of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery (ESC/EACTS). Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2021; 20 (5): 67–72. (in Russian)
24. Schnabel R.B., Pecen L., Rzayeva N., Lucerna M., Purmah Y., Ojeda F.M., et al. Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe. J Am Heart Assoc. 2018; 7 (11): e007559. DOI: https://doi.org/10.1161/jaha.117.007559
25. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42 (5): 373–498. DOI: https://doi.org/10.1093/eurheartj/ehaa945
26. Proietti R., Hadjis A., AlTurki A., Thanassoulis G., Roux J.F., Verma A., et al. A systematic review on the progression of paroxysmal to persistent atrial fibrillation: shedding new light on the effects of catheter ablation. JACC Clin Electrophysiol. 2015; 1 (3): 105–15. DOI: https://doi.org/10.1016/j.jacep.2015.04.010
27. Revishvili A. Sh., Taymasova I.A., Artyukhina E.A., Malyshenlo E.S., Novikov M.V., Strebkova E.D. Mid-term outcomes of thoracoscopic and hybrid therapy of atrial fibrillation. Vestnik aritmologii [Bulletin of Arrhythmology]. 2021; 28 [3 (105)]: 5–12. (in Russian)
28. Mironov N. Yu., Yuricheva Yu.A., Wlodzyanovsky V.V., Sokolov S.F., Dzaurova H.M., Golitsyn S.P., et al. Safety and effectiveness of pharmacologic conversion of atrial fibrillation and flutter: results of multicenter trial. Part II: Assessment of Safety. Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2021; 17 (5): 668–73. (in Russian)